Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model.

ABSTRACT: BACKGROUND:Traumatic brain injury (TBI) is a critical public health and socio-economic problem worldwide. A growing body of evidence supports the involvement of inflammatory events in TBI. It has been reported that resident microglia and infiltrating monocytes promote an inflammatory reaction that leads to neuronal death and eventually behavioral and cognitive impairment. Currently, there is no effective treatment for TBI and the development of new therapeutic strategies is a scientific goal of highest priority. Laquinimod, an orally administered neuroimmunomodulator initially developed for the treatment of multiple sclerosis, might be a promising neuroprotective therapy for TBI. Herein, we aim to investigate the hypothesis that laquinimod will reduce the central nervous system (CNS) damag

SUBMITTER: Katsumoto A 

PROVIDER: S-EPMC5791334 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature